Your Health, We Care
Release date: 2026-01-08 10:29:43 Article From: Lucius Laos Recommended: 119
Ixazomib is a proteasome inhibitor, and its mechanism of action helps kill cancer cells.
Concurrent use of this product with any of the following drugs is generally not recommended, but it may still be necessary in certain cases. If co-administration is indeed required, physicians may adjust the dosage or administration frequency of one or both drugs.
The involved drugs include abrocitinib, live attenuated adenovirus type 4 vaccine, live attenuated adenovirus type 7 vaccine, apalutamide, avacopan, carbamazepine, cholera vaccine, clarithromycin, conivaptan, live attenuated Zaire ebolavirus vaccine, enzalutamide, fedratinib, fexinidazole, fosphenytoin, live attenuated influenza vaccine, itraconazole, letermovir, mifepristone, mitotane, omarigliptin, phenobarbital, phenytoin, primidone, rifampicin, live attenuated rotavirus vaccine, St. John's wort, tazemetostat, and voriconazole.
Certain drugs should be avoided during meals or under specific dietary conditions, as interactions may occur otherwise. Concurrent alcohol consumption or smoking may also trigger interactions. Please discuss the precautions for using this product with food, alcohol, or tobacco with your healthcare provider.
Other health conditions may affect the use of this product. Be sure to inform your physician if you have any other diseases.
1. Heart disease.
2. Peripheral neuropathy (nerve disorders).
3. Thrombocytopenia (low platelet count).
1. Severe renal disease.
2. Moderate to severe hepatic disease.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2622025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4832024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2672025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2772025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2582025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3032025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2652025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2442025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
